Unknown

Dataset Information

0

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.


ABSTRACT: NRAS and BRAF mutations in melanoma inform current treatment paradigms, but their role in survival from primary melanoma has not been established. Identification of patients at high risk of melanoma-related death based on their primary melanoma characteristics before evidence of recurrence could inform recommendations for patient follow-up and eligibility for adjuvant trials.To determine tumor characteristics and survival from primary melanoma by somatic NRAS and BRAF status.A population-based study with a median follow-up of 7.6 years (through 2007), including 912 patients from the United States and Australia in the Genes, Environment, and Melanoma (GEM) Study, with first primary cutaneous melanoma diagnosed in the year 2000 and analyzed for NRAS and BRAF mutations.Tumor characteristics and melanoma-specific survival of primary melanoma by NRAS and BRAF mutational status.The melanomas were 13% NRAS+, 30% BRAF+, and 57% with neither NRAS nor BRAF mutation (wildtype [WT]). In a multivariable model including clinicopathologic characteristics, relative to WT melanoma (with results reported as odds ratios [95% CIs]), NRAS+ melanoma was associated with presence of mitoses (1.8 [1.0-3.3]), lower tumor-infiltrating lymphocyte (TIL) grade (nonbrisk, 0.5 [0.3-0.8]; and brisk, 0.3 [0.5-0.7] [vs absent TILs]), and anatomic site other than scalp/neck (0.1 [0.01-0.6] for scalp/neck vs trunk/pelvis), and BRAF+ melanoma was associated with younger age (ages 50-69 years, 0.7 [0.5-1.0]; and ages >70 years, 0.5 [0.3-0.8] [vs <50 years]), superficial spreading subtype (nodular, 0.5 [0.2-1.0]; lentigo maligna, 0.4 [0.2-0.7]; and unclassified/other, 0.2 [0.1-0.5] [vs superficial spreading]), and presence of mitoses (1.7 [1.1-2.6]) (P?

SUBMITTER: Thomas NE 

PROVIDER: S-EPMC4486299 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6721527 | BioStudies
2005-01-01 | S-EPMC1770697 | BioStudies
2013-01-01 | S-EPMC3978385 | BioStudies
2013-01-01 | S-EPMC3704624 | BioStudies
2019-01-01 | S-EPMC6792090 | BioStudies
2008-01-01 | S-EPMC3808965 | BioStudies
2020-01-01 | S-EPMC7409003 | BioStudies
2018-01-01 | S-EPMC6200630 | BioStudies
2017-01-01 | S-EPMC5581030 | BioStudies
2017-01-01 | S-EPMC5701875 | BioStudies